MedTrace Logo

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT02629848 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 401

Last updated 2015-12-14

No results posted yet for this study

Summary

This study will evaluate progression free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response, and safety of motesanib (AMG706) in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Motesanib

Motesanib (AMG 706) 5 x 25 mg tablets

DRUG

Placebo

Motesanib placebo-matching tablets

DRUG

Paclitaxel

Paclitaxel IV

DRUG

Carboplatin

Carboplatin IV

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-09-30
Completion
2015-03-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629848 on ClinicalTrials.gov